Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Side effects of CAR T-cell therapy

Michael Schmitt • 10 Apr 2019
EBMT 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany, explores the side effects of CD19 CAR T-cell therapy in patients with acute- and non-Hodgkin lymphoma. Prof. Schmitt was speaking at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.

More from Michael Schmitt

2:46
Pros and cons of autologous and allogeneic CAR-Ts
Michael Schmitt • 7 Feb 2022
4:25
Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts
Michael Schmitt • 7 Feb 2022
4:17
Preparing for the commercialization of CAR-T products
Michael Schmitt • 7 Feb 2022
2:55
CD19 CAR T-cell therapy for lymphoma
Michael Schmitt • 26 Apr 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals